Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Asmanex HFA® (mometasone furoate) – Expanded indication, new strength
August 12, 2019 - The FDA approved Merck’s Asmanex HFA (mometasone furoate) inhalation solution, for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.
